Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more